Skip to main content
. 2020 Dec 28;17(12):775–781. doi: 10.11909/j.issn.1671-5411.2020.12.004

Table 1.

Patients' characteristics and the proportion of patients who received appropriate thromboprophylaxis.

Patients' characteristics Overall (n = 396) Patients with appropriate VTE prophylaxis
Data are presented as means ± SD or n (%). *Refers to patients were classified as high risk for VTE if their Padua score was ≥ 4. BMI: body mass index; VTE: venous thromboembolism.
Number of patients 396 (100.0%) 288 (72.7%)
Age, yrs 75.0 ± 9.1 76.0 ± 9.0
Female gender 171 (43.2%) 129 (44.8%)
BMI, kg/m2 27.1 ± 7.4 26.6 ± 7.5
High risk of VTE* 284 (71.7%) 268 (93.1%)
Pre-existing comorbidities
  Hypertension 314 (79.3%) 230 (79.9%)
  Diabetes mellitus 300 (75.8%) 216 (75.0%)
  Chronic kidney disease 140 (35.4%) 103 (35.8%)
  Obesity, BMI > 30 kg/m2 117 (29.5%) 82 (28.5%)
  Heart failure 101 (25.5%) 77 (26.7%)
  Thyroid disorder 50 (12.6%) 37 (12.8%)
  Active cancer 36 (9.1%) 33 (11.5%)
  History of VTE 36 (9.1%) 33 (11.5%)
  Thrombophilic condition 7 (1.8%) 5 (1.7%)
Reason for admission
  Pneumonia 72 (18.2%) 54 (18.8%)
  Urinary tract infection 44 (11.1%) 40 (13.9%)
  Stroke 40 (10.1%) 29 (10.1%)
  Respiratory diseases 30 (7.6%) 25 (8.6%)
  Sepsis 23 (5.8%) 21 (7.3%)
  Decompensated heart failure 16 (4.0%) 10 (3.5%)
  Acute kidney injury 15 (3.8%) 10 (3.5%)
  Other 156 (39.4%) 99 (34.3%)
VTE prophylaxis used
  Heparin 313 (79.0%) 236 (81.9%)
  Enoxaparin 54 (13.6%) 38 (13.2%)
  Mechanical 7 (1.8%) 5 (1.7%)
  None 22 (5.6%) 7 (3.1%)